| CEO Name | Samarth Kulkarni |
| Nationality | India |
| Net Worth Estimation | $60 million |
Samarth Kulkarni's estimated net worth of around $60 million derives primarily from his executive compensation, equity holdings, and stock options accumulated as CEO of CRISPR Therapeutics. His wealth is closely linked to the biotech firm's public valuation, performance, and grants of company shares since his leadership began in 2017.
Samarth Kulkarni, CEO of CRISPR Therapeutics in the biotechnology sector, has an estimated net worth of $60,000,000. This places him at 75% of the maximum estimated CEO net worth within the category and 600% above the minimum.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Samarth Kulkarni Performance in CRISPR Therapeutics
Samarth Kulkarni, CEO of CRISPR Therapeutics, demonstrates visionary leadership by steering the company towards pioneering gene-editing therapies using CRISPR-Cas9 technology. His data-driven decision-making emphasizes strategic partnerships and accelerated clinical development, enhancing the company's innovative pipeline. Under his performance, CRISPR Therapeutics has advanced key treatments, driving significant valuation growth and establishing a leading position in the biotechnology sector.
Latest News
CRISPR Therapeutics: CEO Samarth Kulkarni Leads Company into New Era of Gene Editing
CRISPR Therapeutics, under CEO Samarth Kulkarni, has achieved FDA approval for CRISPR-based treatments for sickle cell disease and beta thalassemia, and is now expanding into therapies for common conditions like high cholesterol and autoimmune diseases. Kulkarni's leadership has driven the company's stock up 65% in 2025, while he continues to focus on making CRISPR therapies more accessible and scalable.
Source: http://www.statnews.com/2025/04/23/biotech-news-crispr-ceo-pay-astrazeneca-bristol-eli-lilly-schizophrenia-drug-the-re/